Mufg Securities在强劲财报和上调指引后增持了Quest Diagnostics的股份。 Mufg Securities boosted its Quest Diagnostics stake after strong earnings and raised guidance.

美国Mufg证券公司在第二季度增加了其在Quest诊断 (DGX) 的股份25.9%,现在持有价值约444,000美元的2,474股股票. Mufg Securities Americas Inc. boosted its stake in Quest Diagnostics (DGX) by 25.9% in Q2, now holding 2,474 shares worth about $444,000. 该公司在10月21日报告了强劲的Q3结果,比估计值高出2.60 EPS-0.09美元,收入为28.2亿美元,比上一年增加13.2%。 The company reported strong Q3 results on October 21, with $2.60 EPS—$0.09 above estimates—and $2.82 billion in revenue, up 13.2% year-over-year. Quest Diagnostics将其2025年全年每股收益指引上调至9.76至9.84美元，并宣布季度股息0.80美元，股息收益率为1.7%。 Quest Diagnostics raised its 2025 full-year EPS guidance to $9.76–$9.84 and announced a quarterly dividend of $0.80, yielding 1.7%. 该股票的市场上限为21.18亿美元,P/E为22.35美元,适度购买共识,目标为196.31美元。 The stock has a market cap of $21.18 billion, a P/E of 22.35, and a moderate buy consensus with a $196.31 target. 内幕人士在这个季度出售了38 118股,而地平线动能家公司则将其股份减少了450股。 Insiders sold 38,118 shares in the quarter, while Horizon Kinetics reduced its stake by 450 shares.